Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion

Annals of Internal Medicine

Volumn 128, Issue 10, 1998, Pages 827-829

  Daar, Eric S ^a,b   Bai, Jiexin ^a,b   Hausner, Mary Ann ^a,c   Majchrowicz, Martin ^a,c   Tamaddon, Mojgan ^a,b   Giorgi, Janis V ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DRUG WITHDRAWAL; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0032524124     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-10-199805150-00005     Document Type: Article

References (20)

1. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324:961-4.
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650-5.
3. Piatak M Jr, Yang LC, Luk KC, Lifson JD, Saag MS, Clark SJ, et al. Viral dynamics in primary HIV-1 infection [Letter]. Lancet. 1993;341:1099.
4. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257-64.
5. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med. 1997;337:1267-74.
6. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA. 1997; 277:1962-9.
7. Markowitz M, Cao Y, Vesanen M, Talal A, Nixon D, Hurley A, et al. Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor [Abstract]. Proceedings of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: 1997:207.
8. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis. 1997;175: 1051-5.
9. Perrin L, Rakik A, Yerly S, Baumberger C, Kinloch-de Loes S, Pechere M, et al. Combined therapy with zidovudine and L-697,661 in primary HIV infection. AIDS. 1996;10:1233-7.
10. Daar ES, Chernyavskiy T, Zhao JQ, Krogstad P, Chen IS, Zack JA. Sequential determination of viral load and phenotype in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 1995;11:3-9.
11. Ferbas J, Daar ES, Grovit-Ferbas K, Lech WJ, Detels R, Giorgi JV, et al. Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. J Virol. 1996;70:7285-9.
12. Giorgi JV, Ho HN, Hirji K, Chou CC, Hultin LE, O'Rourke S, et al. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis. 1994;170:775-81.
13. + cytotoxic t cells express CD38 and HLA-DR antigens. J Immunol. 1993;150:3070-9.
14. Hoen B, Harzic M, Dumon B, Lascoux C, Gomard E, Venet A, et al. Efficacy of zidovudine, lamivudine, and ritonavir combination in patients with symptomatic primary HIV infection: the ANRS 053/538 trial. Can eradication be obtained? [Abstract] 5th Conf Retro and Opportun Infect. 1998:524.
15. Selin LX, Welsh RM. Cytolytically active memory CTL present in lymphocytic choriomeningitis virus-immune mice after clearance of virus infection. J Immunol. 1997;158:5366-73.
16. Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. Nature. 1994;369:648-52.
17. Beverley PC. Is T-cell memory maintained by crossreactive stimulation? Immunol Today. 1990;11:203-5.
18. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997;276:960-4.
19. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188-91.
20. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-8.